Search Results - "Estela, Ana Clopés"

An international comparative analysis and roadmap to sustainable biosimilar markets by Alnaqbi, Khalid A., Bellanger, Agnès, Brill, Alex, Castañeda-Hernández, Gilberto, Clopés Estela, Ana, Delgado Sánchez, Olga, García-Alfonso, Pilar, Gyger, Pius, Heinrich, Daniel, Hezard, Germain, Kakehasi, Adriana, Koehn, Cheryl, Mariotte, Olivier, Mennini, Francesco, Mayra Pérez-Tapia, Sonia, Pistollato, Michele, Saada, Rowan, Sasaki, Tadanori, Tambassis, George, Thill, Marc, Werutsky, Gustavo, Wilsdon, Tim, Simoens, Steven

“…Background: Although biosimilar uptake has increased (at a variable pace) in many countries, there have been recent concerns about the long-term sustainability…”
Get full text

Characterization of the Pharmaceutical Risk-Sharing Arrangement Process in Catalonia by Reyes-Travé, Anna, Guarga-Solé, Laura, Roig-Izquierdo, Marta, Alonso-Pérez, Enrique, Clopés-Estela, Ana, Delgadillo-Duarte, Joaquín

“…Pharmaceutical risk-sharing arrangements have emerged as a reasonable tool to promote sustainable access to innovative medicines with uncertain clinical…”
Get full text

Survey of oncohematological pharmaceutical care situation in Spain by Martínez-Bautista, María José, Mangues-Bafalluy, Irene, Cajaraville-Ordoñana, Gerardo, Carreras-Soler, María Josep, Clopés-Estela, Ana, Moreno-Martínez, Estela

“…To learn about the baseline of Oncohematological Pharmacy Units in Spanish hospitals in order to identify areas for  improvement. A survey in line with the…”
Get more information

Pharmacotherapeutic management of advanced therapy medicinal products by Poveda-Andrés, José Luis, Ruiz-Caldes, María José, Carreras-Soler, María José, Clopés-Estela, Ana, Flores-Moreno, Sandra, García-Pellicer, Javier, Giráldez-Quiroga, Míriam, López-Briz, Eduardo, Lozano-Blázquez, Ana, Megías-Vericat, Juan Eduardo, Tordera-Baviera, María, Valero-García, Silvia

“…Advanced therapy medicinal products have emerged In recent years as new pharmacotherapeutic strategies. In this context, hospital pharmacy services have had to…”
Get full text

Economic evaluation of the GENESIS-SEFH report of olaratumab with doxorubicin in soft tissue sarcoma in advanced stages by Del Río-Valencia, Juan Carlos, Asensi-Díez, Rocío, Villalobos-Torres, Lorenzo, Clopés-Estela, Ana, Fraga-Fuentes, M ª Dolores

“…The economic evaluation of the drug olaratumab is carried out in the treatment of soft tissue sarcoma. The data were analyzed following the recommendations…”
Get more information

Interacción entre tratamientos oncológicos y soporte nutricional by Fort Casamartina, Eduard, Arribas Hortiguela, Lorena, Bleda Pérez, Carmen, Muñoz Sánchez, Carme, Peiro Martínez, Imma, Perayre Badía, María, Clopés Estela, Ana

“…Durante la última década, el conocimiento de nuevos mecanismos implicados en el desarrollo del cáncer ha permitido el diseño de nuevos fármacos para su…”
Get full text

[Translated article] Characteristics, clinical benefit, and reimbursement of new authorisations for oncohaematology drugs in Spain between 2017 and 2020 by Martínez-Barros, Hilario, Pousada-Fonseca, Álvaro, Pedreira-Bouzas, Jorge, Clopés-Estela, Ana

“…To describe the authorisations and funding resolutions for new onco-haematological drugs in Spain between 2017 and 2020, as well as the results of their main…”
Get full text

DPYD genotyping and 5-fluoropyrimidine toxicity: An overview of systematic reviews protocol by Torres, Sara Otero, Pérez, Olalla Montero, Mauriz, Rosa Rodríguez, Casamartina, Eduard Fort, Martínez, Sandra Fontanals, Estela, Ana Clopés

“…The increased risk of severe and life-threatening toxicity in patients with dihydropyridine dehydrogenase (DPD) deficiency, under treatment with…”
Get full text

Pay-for-performance schemes: 10 years’ experience in a comprehensive cancer center by Clopés Estela, Ana, Soler Rotllant, Francesc, Germà Lluch, José Ramón, Calle Rodríguez, Candela

Get full text

Pay-for-performance schemes: 10 years' experience in a comprehensive cancer center by Clopés Estela, Ana, Soler Rotllant, Francesc, Germà Lluch, José Ramón, Calle Rodríguez, Candela

Get more information

Características, beneficio clínico y financiación de las nuevas autorizaciones de fármacos oncohematológicos en España entre 2017 y 2020 by Martínez-Barros, Hilario, Pousada-Fonseca, Álvaro, Pedreira-Bouzas, Jorge, Clopés-Estela, Ana

“…describir las autorizaciones y resoluciones de financiación de nuevos fármacos oncohematológicos en España entre 2017 y 2020, así como los resultados de sus…”
Get full text

[Artículo traducido] Genotipado del gen DPYD y toxicidad de las 5-fluoropirimidinas: protocolo de un resumen de revisiones sistemáticas by Otero Torres, Sara, Montero Pérez, Olalla, Rodríguez Mauriz, Rosa, Fort Casamartina, Eduard, Fontanals Martínez, Sandra, Clopés Estela, Ana

“…el incremento del riesgo de toxicidad grave y potencialmente mortal en los pacientes con deficiencia de dihidropiridina deshidrogenasa en tratamiento con…”
Get full text

Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer; GENESIS-SEFH drug evaluation reporta by Bosch, María Espinosa, Díez, Rocío Asensi, Agudo, Sara García, Estela, Ana Clopés

“…Nintedanib is a triple angiokinase inhibitor that has been approved by the European Agency Medicines (EMA) in combination with docetaxel for the treatment of…”
Get full text

DPYD genotyping and 5-fluoropyrimidine toxicity: An overview of systematic reviews protocol by Torres, Sara Otero, Pérez, Olalla Montero, Mauriz, Rosa Rodríguez, Casamartina, Eduard Fort, Martínez, Sandra Fontanals, Estela, Ana Clopés

“…The increased risk of severe and life-threatening toxicity in patients with dihydropyridine dehydrogenase (DPD) deficiency, under treatment with…”
Get more information

Interacción entre tratamientos oncológicos y soporte nutricional by Fort Casamartina, Eduard, Arribas Hortiguela, Lorena, Bleda Pérez, Carmen, Muñoz Sánchez, Carme, Peiro Martínez, Imma, Perayre Badía, María, Clopés Estela, Ana

“…Durante la última década, el conocimiento de nuevos mecanismos implicados en el desarrollo del cáncer ha permitido el diseño de nuevos fármacos para su…”
Get full text

Usefulness and Safety Evaluation of Chemotherapy Administration Device for Nurses: Experimental Study by Serra-Barril, M. Antònia, Pamias-Nogue, Marta, Zarza-Arnau, Núria, Esteve-Gomez, Anna, Clopes-Estela, Ana, Fernández-Ortega, Paz

“…Antineoplastic drugs are considered high risk, and computerized systems favor safe administration. The objective of the study was to test the usefulness and…”
Get full text

Not Available by t Casamartina, Eduard, Arribas Hortiguela, Lorena, Bleda Pérez, Carmen, Muñoz Sánchez, Carme, Peiro Martínez, Imma, Perayre Badía, María, Clopés Estela, Ana

“…Durante la última década, el conocimiento de nuevos mecanismos implicados en el desarrollo del cáncer ha permitido el diseño de nuevos fármacos para su…”
Get full text

Pharmacotherapeutic management of advanced therapy drugs by Poveda-Andrés, José Luis, Ruiz-Caldes, María José, Carrera-Soler, María José, Clopés-Estela, Ana, Flores-Moreno, Sandra, García-Pellicer, Javier, Giráldez-Quiroga, Míriam, López-Briz, Eduardo, Lozano-Blázquez, Ana, Megías-Vericat, Juan Eduardo, Tordera-Baviera, María, Valero-García, Silvia

“…Advanced therapy drugs have emerged in recent years as new pharmacotherapeutic strategies. In this context, hospital pharmacy services have had to adapt to the…”
Get more information

Posicionamiento del farmacéutico de hospital ante la utilización de medicamentos en condiciones diferentes a las autorizadas by Delgado, Olga, Puigventós, Francesc, Clopés, Ana

Get full text

Off-label use of oncology drugs: national survey results by González-Haba Peña, Eva, Agustín Ferrández, María José, Mangues Bafalluy, Irene, Alfredo López, Nicolás, Fraga Fuentes, María Dolores, Marín Gil, Roberto, Martínez Bautista, María José, Clopés Estela, Ana

“…identify by means of a survey the off-label treatments more often used in the oncohaematology area, as well as to know the established procedures and criteria…”
Get more information